Clinical Applications of PET in Oncology

Eric M. Rohren, Timothy G. Turkington, R. Edward Coleman

Research output: Contribution to journalReview article

642 Scopus citations

Abstract

Positron emission tomography (PET) provides metabolic information that has been documented to be useful in patient care. The properties of positron decay permit accurate imaging of the distribution of positron-emitting radiopharmaceuticals. The wide array of positron-emitting radiopharmaceuticals has been used to characterize multiple physiologic and pathologic states. PET is used for characterizing brain disorders such as Alzheimer disease and epilepsy and cardiac disorders such as coronary artery disease and myocardial viability. The neurologic and cardiac applications of PET are not covered in this review. The major utilization of PET clinically is in oncology and consists of imaging the distribution of fluorine 18 fluorodeoxyglucose (FDG). FDG, an analogue of glucose, accumulates in most tumors in a greater amount than it does in normal tissue. FDG PET is being used in diagnosis and follow-up of several malignancies, and the list of articles supporting its use continues to grow. In this review, the physics and instrumentation aspects of PET are described. Many of the clinical applications in oncology are mature and readily covered by third-party payers. Other applications are being used clinically but have not been as carefully evaluated in the literature, and these applications may not be covered by third-party payers. The developing applications of PET are included in this review.

Original languageEnglish (US)
Pages (from-to)305-332
Number of pages28
JournalRadiology
Volume231
Issue number2
DOIs
StatePublished - May 1 2004

Keywords

  • Breast neoplasms, PET
  • Gastrointestinal tract, PET
  • Head and neck neoplasms, PET
  • Lung neoplasms, PET
  • Lymphoma, PET
  • Melanoma
  • Review

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging

Fingerprint Dive into the research topics of 'Clinical Applications of PET in Oncology'. Together they form a unique fingerprint.

Cite this